Press Releases Archives - Page 3 of 10

Achieving Security Certifications Demonstrates the Company’s Continued Commitment to Securing Patient Health Data

PALO ALTO, CA, November 3, 2022 – Glooko Inc. (“Glooko”), today announced achieving SOC 2 Type II certification and renewal of HITRUST certification for Glooko®, its industry leading connected care platform for people with chronic conditions. Glooko has a longstanding commitment to protecting sensitive data and information, and understands the growing importance in healthcare to meet complex compliance and privacy requirements.

Developed by HITRUST, the standards and certification body that helps organizations achieve information security, privacy, and regulatory compliance goals through comprehensive and innovative solutions, the HITRUST Risk-based, 2-year (r2) Certification is the industry gold standard, combining security standards set by HIPAA, NIST, COBIT, and many more. Glooko’s HITRUST recertification places the company in an elite group of organizations worldwide, proving that its attested security controls meet these standards of protecting patient health data.

Along with the two-year HITRUST recertification, the Company has achieved SOC 2 Type II certification, which follows its SOC 2 Type I certification achieved late last year. This extensive reporting standard provides independent validation from a sophisticated, Silicon Valley based third-party auditing firm that Glooko has all the required controls in place for their employees, systems and processes to ensure the security of customers’ data, its software and company. These accredited 3rd-party auditors have certified that Glooko’s attested security controls and policies work extremely well in securing patient health data.

“Organizations like ours are continually under pressure to meet complex compliance and privacy requirements that include technical and process elements such as NIST and ISO,” said Prakash Menon, Chief Technology Officer at Glooko. “We are pleased to demonstrate to our customers our commitment to the highest standards for data protection and information security by achieving these rigorous third-party certifications.”

“In today’s ever-changing threat landscape, HITRUST is continually innovating to find new and creative approaches to address challenges,” said Jeremy Huval, Chief Innovation Officer, HITRUST. “Glooko’s HITRUST Risk-based, 2-year Certification is evidence that they are at the forefront of industry best practices for information risk management and compliance.”

For more information: https://glooko.com/trust-privacy/

About Glooko
Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations. For more information, please visit glooko.com.

###

Media Contact
Tanya Rodante
Director of Global Communications
[email protected]

Company Honored With a Gold for News Coverage for its Thought Leadership on Remote Patient Monitoring

PALO ALTO, CA, August 23, 2022 – Glooko Inc. (“Glooko”), a leading provider of intelligent, connected care solutions and remote patient monitoring (RPM) for people with chronic conditions, today announced that the Company earned gold honors for their work in thought leadership and earned media placements.

The dotCOMM Awards is administered and judged by the Association of Marketing and Communication Professionals (AMCP), one of the largest, oldest and most respected evaluators of creative work in the marketing and communication industry. Since its inception in 1994, AMCP has judged over 200,000 entries from throughout the world.

“We’re honored to be recognized by the dotCOMM community for our thought leadership in connected care technology and specifically, remote patient monitoring,” said Zach Henderson, Chief Commercial Officer at Glooko. “This award is a testament to our commitment to increasing awareness and education among healthcare providers on the benefits of connected, remote care, and ultimately improving the lives of people with chronic conditions through these innovations.”

The gold award recognition acknowledges the level of the Company’s 2021 coverage in healthcare media and digital health publications, bylined by Glooko’s Chief Medical Officer, Dr. Mark Clements, as a contributing author.

Glooko’s connected care platform, and specifically its remote patient monitoring solution, has seen record adoption since 2020.

About dotCOMM Awards
The dotCOMM Awards is an international competition that celebrates brilliance in web creativity and digital communication. The competition is unique in that it reflects the role of creatives in the dynamic web that is transforming how we market and communicate products and services. The awards are administered and judged by the Association of Marketing and Communication Professionals (AMCP), a leading organization of evaluators of creative work in the ever-evolving marketing and communication space. To learn more about the dotCOMM Awards and explore the full list of champions, visit www.dotcommawards.com.

###

Media Contact
Tanya Rodante
Director of Global Communication
[email protected]

Expanding Availability of Diabetes Medical Education Programme for Healthcare Providers

Gothenburg, Sweden (PR NEWSWIRE) — July 13, 2022 — Glooko AB (“Glooko”) today announced, in partnership with the Diabetes Technology Network (DTN)/ Association of British Clinical Diabetologists (ABCD), the expansion into Ireland of Academy, the company’s online medical education programme for clinicians who treat people with diabetes. Originally inspired after discussions with the National Health Service England (NHSE) as part of its effort to ensure all healthcare professionals learn uniformly about technology, the programme will help clinicians further increase their knowledge and stay current on the ever-growing assortment of new diabetes technologies.

According to the International Diabetes Federation, Ireland, with a population of just five million people, is ranked 7th in the world for diabetes-related health expenditure per person. For people with diabetes and their healthcare providers, managing the myriad technologies like glucose monitors and insulin pumps, and the data volumes accompanying these technologies, is a well-established challenge. Technology tools like web-based programs, telehealth, mobile apps and remote monitoring are improving users’ accessibility and connectivity, but adoption of these innovations can be slow and complicated.

Academy focuses exclusively on diabetes health technology and education. The programme includes an extensive range of online courses for healthcare providers (HCPs) to increase expertise and mastery of these technologies, to help deploy them to people with diabetes. All courses are accessed through the Glooko® platform or the ABCD website.

Ireland is the second country to implement Academy in Glooko’s plans to provide the program globally. Since launching in the UK in October of 2020, over 1,000 clinicians across more than 300 clinics have registered for the programme, with more than 750 Continuing Professional Development (CPD) certificates awarded.

“We are extremely pleased with the successful adoption of Academy in the UK,” said Russ Johannesson, CEO of Glooko. “We are particularly excited to continue our expansion and offer the programme in Ireland. Our goal is to not only equip primary care and specialist HCPs with the technological skill set relevant to their professional development, but to also support them in building a wider range of capabilities, as treating chronic conditions moves increasingly towards a more digital world.”

Pratik Choudhary, Professor of Diabetes at University of Leicester, Professor/Honorary Consultant in Diabetes and Chair of DTN UK, stated, “Given the rapidly changing landscape of diabetes technologies, it is very important for healthcare professionals to have a trusted resource for training. The Diabetes Technology Network UK is quite pleased to be able to bring the training of Academy to Ireland and support healthcare professionals using the latest diabetes technology.”

The programme is available to all diabetes healthcare professionals in Ireland at no cost and was funded in part via sponsorships from global industry partners like AgaMatrix, Dexcom, Lilly, mylife Diabetescare, Novo Nordisk and Roche. Production was provided by DigiBete (DigiBete Global, Leeds, UK), which remains actively involved in Academy. The curriculum covers the majority of the diabetes devices and technologies, and HCPs that complete the programme will receive CPD accreditation as well as DTN UK/ABCD certification.

Glooko is committed to incorporating newly-developed, online immersive education experiences that complement the Company’s portfolio of industry-leading digital health solutions. Academy is part of Glooko’s global mission to enhance the lives of people with chronic conditions by connecting them with their HCPs and equipping both with the tools needed to achieve improved outcomes.

For more information: go.glooko.com/academy

Sources:
1. International Diabetes Federation Diabetes Atlas (2021)
2. https://worldpopulationreview.com/countries/ireland-population

###

Media Inquiries
Tanya Rodante
Director of Global Communication, Glooko
[email protected]

PALO ALTO, CA, April 27, 2022 /PRNewswire/ – Glooko, Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the appointment of Alfonso “Chito” Zulueta to its Board of Directors.

Respected as a leader with a strong track record of success in the pharmaceutical industry and deep experience on corporate boards and industry associations, Mr. Zulueta comes to the Glooko Board having served as a senior executive leading a wide range of global business and commercial units over his more than 30-year career with Eli Lilly and Company (NYSE: LLY). The Glooko leadership team and Board welcome the breadth and depth of experience he brings as the company continues its strategic growth as a digital health leader in chronic disease management.

“We are very excited for Chito to join our Board and particularly fortunate for his strong understanding of the impact that digital health solutions can have on managing chronic diseases,” said Russ Johannesson, CEO of Glooko. “He brings a wealth of valuable experience and unique perspectives to our Board, having led successful global healthcare ventures focused on treating diabetes and other diseases. Chito’s appointment comes at a critical time for Glooko, as we continue to broaden our digital therapeutics (DTx) and clinical research businesses.”

Mr. Zulueta retired at the end of 2021 from his roles at Lilly as an executive committee member, corporate officer and president of the company’s international business unit, where he was responsible for leading Lilly’s business in all geographies outside of the U.S. and Canada. Prior to that, he served as Lilly’s president of its Emerging Market business unit, president of Japan, president of Global Oncology and Critical Care product group, vice president in charge of U.S. sales and marketing for the neuroscience and diabetes/family health business unit, and vice president of global marketing.

“This is a compelling time to join the Glooko Board as the Company expands its offerings and commercial footprint,” said Mr. Zulueta. “Glooko is rapidly increasing its market relevance and is driving real innovation through its digital health solutions, serving more patients and healthcare professionals globally. I’m excited to leverage my experience and insights to help Glooko accelerate this growth and evolution.”

Mr. Zulueta also serves on the boards of directors of CTS Corporate (NYSE: CTS), Syneos Health (NASDAQ: SYNH), and Calidi Biotherapeutics, Inc. He served previously on the boards of industry associations, including the European Federation of Pharmaceutical Industries and Associations (chairman of the international committee), PhRMA (chairman of the Japan business executive committee), the American Chamber of Commerce of Japan (governor of the Kansai chapter), and the U.S.- Japan Business Council.

Mr. Zulueta earned an MBA from the Darden School of Business Administration of the University of Virginia and a bachelor’s degree in economics from De La Salle University.

About Glooko
Glooko is transforming digital health by connecting people with diabetes and related chronic conditions with their healthcare teams, enabling collaborative telehealth, clinical research and improved health outcomes. The company’s software platforms collect and analyze data from multiple devices in one highly secure place, allowing for easy remote upload via app or in-clinic, and producing easy-to-read analytics through actionable charts and graphs. The platform is compatible with over 95% of global diabetes and health monitoring devices, giving patients and their providers flexibility in how to manage their conditions. With over 35 billion data points, Glooko is the global leader in diabetes patient data. Glooko’s solutions can be found in 31 countries across 22 languages. Learn more at glooko.com.

###

Media Inquiries:
Tanya Rodante
Director of Global Communication, Glooko
[email protected]

Paris-based health platform provides diabetes remote monitoring and enhances physician-patient collaboration

PALO ALTO, CA AND PARIS, FRANCE, March 16, 2022 /PRNewswire/ – Glooko Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can work together to improve health outcomes.

DIABNEXT’s mobile app complements Glooko’s product portfolio and tracks diabetes data so that physicians can collaborate with their patients to monitor individual patient data and provide remote care. DIABNEXT already has a strong presence in France, and under the Glooko product umbrella, can significantly increase the number of patients and healthcare providers in the territory and expand remote patient monitoring offerings.

“We are very pleased to welcome the DIABNEXT team to Glooko and especially excited to add their well-regarded product to Glooko’s portfolio, along with their expertise in the diabetes community in France,” said Russ Johannesson, CEO of Glooko. “The addition of DIABNEXT expands our offerings with a unique platform that can help us better customize the patient experience and improve health outcomes for people with diabetes. Glooko’s acquisition of DIABNEXT further cements our commitment to increase our global presence and continue to drive innovative solutions.”

The DIABNEXT team has joined the Glooko team in the company’s Paris office and will offer both platforms to the French market. Glooko’s goal is to serve more patients with diabetes as well as related chronic conditions. The former CEO of DIABNEXT, Laurent Nicolas, is the Managing Director and will lead the efforts in France.

“The DIABNEXT team is excited to be part of Glooko. We appreciate the value Glooko places on the product solutions developed for the unique needs of the French market,” said Laurent Nicolas. “Not only will this allow us to continue to serve the diabetes community, but with Glooko’s resources and capabilities in device integration, we can now offer more tools to help healthcare professionals provide better care across diabetes-related chronic conditions for the patients they serve.”

All existing patients, hospitals and clinics currently using the DIABNEXT product will continue to be supported on the platform. Glooko is working to expand the adoption of the French Ministry of Health’s ETAPES program, which was designed to support innovative digital health solutions.

This should come as welcome news to French healthcare professionals that are familiar with DIABNEXT and its in-depth understanding of physician and patient needs. “DIABNEXT makes a unique and essential contribution to the management of diabetes,” stated Professor Charles Thivolet, Diabetologist, Director and Co-Founder of DIABe-CARE center. “With its remote monitoring solution already in place at the Hospices Civils de Lyon, DIABNEXT allows us to improve the healthcare pathway for our patients as well as personalize patient follow-up. Together with DIABe-CARE, Diabnext is at the forefront of remote patient monitoring in France, supporting the French initiative to provide innovative technologies in the health sector.”

The DIABNEXT platform will be marketed under the name Glooko XT™.

About Glooko
Glooko is transforming digital health by connecting people with diabetes and related chronic conditions with their healthcare teams, enabling collaborative telehealth, clinical research and improved health outcomes. The company’s software platforms collect and analyze data from multiple devices in one highly secure place, allowing for easy remote upload via app or in-clinic, and producing easy-to-read analytics through actionable charts and graphs. The platform is compatible with over 95% of global diabetes and health monitoring devices, giving patients and their providers flexibility in how to manage their conditions. With over 35 billion data points, Glooko is the global leader in diabetes patient data. More than 3 million users have already benefited from Glooko’s solutions in 31 countries across 22 languages. Learn more at glooko.com.

About DIABNEXT
DIABNEXT was founded with the vision of developing highly innovative solutions that help people with diabetes better manage their chronic condition and improve their care and quality of life. Through collaboration with many leaders and clinicians in diabetes healthcare, the DIABNEXT platform offers patients a unique solution that enables remote monitoring, coordination, therapeutic education and analytics of data related to blood glucose, insulin, diet and physical activity automatically through connected health devices.

# # #

Media, North America
Tanya Rodante
Director of Global Communication, Glooko
[email protected]

Media, Europe
Isabelle Gueguen
Marketing Manager, Glooko
[email protected]
+33 7 60 31 46 76

L’entreprise basée à Paris propose une plateforme de télésurveillance du diabète qui améliore la collaboration patient-praticien

Palo Alto, Californie (États-Unis) et Paris (France), le 16 mars 2022 – Glooko Inc., l’un des principaux fournisseurs de solutions de télésurveillance de patients et de gestion des données pour le diabète et les autres maladies chroniques, annonce aujourd’hui l’acquisition de DIABNEXT. Installée à Paris, cette entreprise propose une plateforme de télémédecine qui aide les patients diabétiques à mieux gérer leur maladie et à rester en contact, à distance, avec les professionnels de santé qui les suivent, afin d’améliorer l’équilibre de leur diabète.

L’application mobile DIABNEXT vient compléter le portefeuille produits de Glooko. Elle permet de suivre à distance les indicateurs essentiels à la prise en charge du diabète, facilitant la collaboration des médecins avec leurs patients afin de mieux prendre en charge la maladie. DIABNEXT dispose déjà d’une bonne implantation en France, et en rejoignant la famille Glooko, elle pourra accroître de façon significative le nombre de ses utilisateurs – patients et professionnels de santé sur le territoire national, tout en élargissant son offre de suivi à distance des patients.

« Nous sommes très heureux d’accueillir l’équipe de DIABNEXT au sein de Glooko. Ils disposent d’une expertise reconnue dans le secteur du diabète en France, et nous sommes particulièrement ravis d’intégrer leur produit déjà établi à notre offre », indique Russ Johannesson, PDG de Glooko. « En accueillant DIABNEXT, nous enrichissons notre offre d’une plateforme sans équivalent qui va nous aider à mieux personnaliser l’expérience patient et à améliorer la qualité de vie des personnes diabétiques. L’acquisition de DIABNEXT par Glooko confirme notre engagement à accroître notre présence mondiale et à proposer des solutions innovantes en permanence. »

L’équipe de DIABNEXT rejoint l’équipe Glooko au sein du bureau parisien de la société et propose désormais les deux plateformes sur le marché français. Glooko ambitionne de développer la communauté des patients diabétiques ou souffrant d’autres maladies chroniques, utilisateurs de ses plateformes. Laurent Nicolas, précédemment DG de DIABNEXT, pilote désormais les activités en France au poste de directeur général.

« Nous sommes ravis de rejoindre Glooko, une société dont nous apprécions les valeurs et qui permettra de développer des produits répondant spécifiquement aux besoins du marché français », souligne Laurent Nicolas. « Nous pourrons non seulement continuer à servir la communauté des patients diabétiques, mais nous pourrons également, en nous appuyant sur les ressources et les capacités d’intégration de Glooko, offrir plus d’outils pour aider les professionnels de santé à mieux accompagner leurs patients souffrant de maladies chroniques liées au diabète. »

Les patients, hôpitaux et cliniques qui utilisent actuellement le produit DIABNEXT continueront d’être pris en charge sur la plateforme. Glooko travaille actuellement sur le passage dans le droit commun du programme ETAPES (Expérimentations de télémédecine pour l’amélioration des parcours en santé) du Ministère des Solidarités et de la Santé. Ce programme vise à encourager et à soutenir le déploiement de projets de télésurveillance sur l’ensemble du territoire.

Il s’agit d’une bonne nouvelle pour les professionnels de santé français qui connaissent DIABNEXT et dont ils apprécient sa compréhension fine des besoins des médecins et des patients. « DIABNEXT apporte une contribution unique et essentielle à la prise en charge du diabète », déclare le Professeur Charles Thivolet, diabétologue, directeur et co-fondateur du centre DIABe-CARE. « Avec sa solution de télésurveillance déjà en place aux Hospices Civils de Lyon, DIABNEXT nous permet d’améliorer le parcours de soins et de personnaliser le suivi des patients. Avec DIABe-CARE, DIABNEXT est à la pointe de la télésurveillance des patients en France, et vient soutenir l’ambition française de fournir des technologies innovantes au secteur de la santé. »

La plateforme DIABNEXT sera commercialisée sous le nom de Glooko XT™.

A propos de Glooko
Glooko transforme la santé numérique en mettant en contact les personnes atteintes de diabète et d’autres maladies chroniques avec leurs équipes de soins de santé, ce qui favorise la télésanté collaborative, la recherche clinique et l’amélioration des résultats en matière de santé. Les plateformes logicielles de l’entreprise collectent et analysent les données de plusieurs appareils dans un seul endroit hautement sécurisé, ce qui permet un téléchargement à distance facile via une application ou en clinique, et produit des analyses faciles à lire grâce à des tableaux et des graphiques exploitables. La plateforme est compatible avec plus de 95 % des dispositifs mondiaux de surveillance du diabète et de la santé, ce qui donne aux patients et à leurs fournisseurs une flexibilité dans la prise en charge de leurs maladies. Avec plus de 35 milliards de données, Glooko est le leader mondial des données sur les patients diabétiques. Plus de 3 millions d’utilisateurs bénéficient déjà des solutions de Glooko dans 31 pays en 22 langues. Pour en savoir plus, consultez le site www.glooko.com

A propos de DIABNEXT
DIABNEXT a été fondée en vue de développer des solutions très innovantes qui aident les personnes diabétiques à mieux gérer leur maladie et à améliorer leurs soins et leur qualité de vie. Grâce à des collaborations avec de nombreux leaders d’opinion et cliniciens spécialisés en diabète, la plateforme DIABNEXT offre aux patients une solution unique automatisée qui permet la télémédecine, la coordination des équipes soignantes, l’éducation thérapeutique et le suivi à distance des données liées à la glycémie, à l’insuline, à l’alimentation et à l’activité physique, en se connectant à des dispositifs de santé.

Média, Amérique du Nord
Tanya Rodante
Directrice de la communication, Glooko
[email protected]

Média, Europe
Isabelle Guéguen
Responsable marketing, Glooko
[email protected]
+33 7 60 31 46 76

Combined Offering Provides all the Components of an End-to-End Platform

PALO ALTO, California, March 3, 2022 /PRNewswire/ – Glooko, Inc., a leading provider of remote patient monitoring and digital health solutions for diabetes and other chronic conditions, today announced a collaboration with Johns Hopkins HealthCare Solutions. Glooko’s cloud-based, device-agnostic platform and patient app will provide vitals capture and tracking enablement to the Johns Hopkins Blossom™ program, an interactive management program for people with diabetes, offered through employers, health plans and health care providers.

The Blossom solution provides an interactive experience that combines biometric data tracking, personalized skill-building content, and support from coaches to help people with diabetes better assess, understand, and optimize their care and build a healthier lifestyle. Blossom was developed to make diabetes management easier through lifestyle modifications while significantly improving health outcomes and reducing the cost of care.

“Glooko is pleased to work with Johns Hopkins HealthCare Solutions to enable a solution that helps patients, employees and health plan members succeed in making positive lifestyle adjustments and improve connections with their care teams, leading to better health,” said Glooko CEO Russ Johannesson. “Opportunities like the Blossom collaboration further expand Glooko’s value and offerings for our health care provider, payer and employer customers. We look forward to continuing to create real and meaningful differences in the lives of people with chronic conditions like diabetes, while reducing the cost of their care.” Published research has shown that remote patient monitoring coupled with clinically proven behavior change protocols can improve health outcomes among people with diabetes and reduces costs*.

Glooko’s cloud-based digital health platform and patient app integrate seamlessly into the Blossom solution, meeting patients where they are on their journey to better health. Glooko’s data tracking and sharing allows Blossom coaches and customer care teams to provide continuity of care in between doctors’ appointments–through personalized diabetes education content, care coordination and a 365-day coaching program–by identifying and closing any gaps in patient care. The ability to remotely share data also makes it possible to equip care teams with continual data to identify at-risk patients, intervene as needed, and provide more personalized, informed care.

The solution is available to payers, providers and self-insured employers immediately.

About Glooko
Glooko is transforming digital health by connecting people with diabetes and other chronic conditions with their healthcare teams, enabling collaborative telehealth, clinical research and improved health outcomes. The company’s software platforms collect and analyze data from multiple devices in one highly secure place, allowing for easy remote upload via app or in-clinic, and producing easy-to-read analytics through actionable charts and graphs. The platform is compatible with over 95% of global diabetes and health monitoring devices, giving patients and their providers flexibility in how to manage their conditions. With over 35B+ data points, Glooko is the global leader in diabetes patient data. More than 3 million users have already benefited from Glooko’s solutions in 29 countries across 22 languages. Learn more at glooko.com.

* Sources:
1. Tong Sheng, Linda Parks, Sarine Babikian, Vikram Singh, Mark A. Clements. Immediate and Sustained Trends in Glycemic Control during Remote Patient Monitoring in People with Type 2 Diabetes. ADA Scientific Sessions. June 2021
2. Tong Sheng, Linda Parks, Sarine Babikian, Vikram Singh, Michael Greenfield, Mark A. Clements Glycemic Improvements Following Mobile-Enabled Remote Patient Monitoring: A Randomized Control Study. ADA Scientific Sessions. June 2020.
3. Mark A Clements, Janelle Duffee, Dawn McCarther. Remote patient monitoring for adults with type 2 diabetes. ADCES Research Sessions. August 2020.
4. Maureen J. Lage & Kristina S. Boye (2020) The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database, Current Medical Research and Opinion, 36:9, 1441-1447, DOI: 10.1080/03007995.2020.1787971

###

Media Inquiries
Tanya Rodante
Director of Global Communication, Glooko
[email protected]

– Transaktion erweitert Glookos Expertise um Machine Learning und Just-In-Time Adaptive Intervention (JITAI) Technologien
– Digitale Interventionssysteme für chronische Erkrankungen

BERLIN, Deutschland, und PALO ALTO, USA. 31. Januar 2022 /PRNewswire/ – Glooko, Inc., ein führender Anbieter von Datenmanagement- und Telemonitoringlösungen für Diabetes und andere chronische Erkrankungen, gab heute die Akquisition des Berliner Digital Health Unternehmens xbird bekannt. xbird entwickelt Technologien, die Patienten und Gesundheitsversorgern die Vorhersage von Verhaltensmustern ermöglichen. Durch xbirds führende Just-In-Time Adaptive Intervention (JITAI) Technologie kann die Diabetestherapie individuell personalisiert werden.

xbirds Technologie wertet medizinische Daten und Verhaltensmuster gezielt aus, um daraus mithilfe neuester Erkenntnisse aus künstlicher Intelligenz (KI) und maschinellem Lernen (ML) Gesundheitsrisiken von Diabetespatienten zu identifizieren und maßgeschneiderte Vorschläge für die Therapie und den Lebensstil des einzelnen Patienten zu machen. Sensoren von Smartphones und Wearables zeichnen die Bewegungen von Patienten auf; die Daten werden analysiert, um individuelle Verhaltensmuster und personalisierte Vorschläge zur Verbesserung des Lebensstils und der Therapie von Patienten zu erstellen. Die Übernahme von xbird ergänzt die analytischen Kapazitäten und Technologien von Glooko und ermöglicht somit eine Weiterentwicklung von Glookos Plattform.

“Wir freuen uns sehr, das Team von xbird in der Glooko-Familie willkommen zu heißen. Unsere Investition in xbird steht für unser strategisches Interesse an maschinellem Lernen und personalisiertem digitalen Coaching von chronisch kranken Patienten”, sagte Russ Johannesson, Geschäftsführer von Glooko. “Unter den vielen JITAI Firmen im Digital Health Sektor verfügt xbird ganz klar schon heute über eine überlegene Lösung und hat erfolgreiche Partnerschaften mit Herstellern von Diabetesgeräten und klinischen Einrichtungen abgeschlossen. Die Kombination von Glookos globaler Präsenz und xbirds wegweisender JITAI Expertise wird es uns ermöglichen, die medizinische Versorgung von Patienten weiter zu verbessern.”

Sebastian Sujka, Gründer und Geschäftsführer von xbird, ergänzt: “xbird und Glooko passen großartig zusammen. Wir teilen unser Engagement für intelligente digitale Lösungen, die die Therapie von chronischen Erkrankungen verbessern und messbare Resultate liefern. Außerdem sind wir entschlossen, allen Patienten breitgefächerte medizinische Unterstützung zu bieten. Unser Ziel ist die Weiterentwicklung digitaler Gesundheitslösungen für möglichst viele Menschen mit chronischen Erkrankungen.” Die Glooko GmbH übernimmt alle Mitarbeiter von xbird und wird von Sebastian Sujka als Geschäftsführer geleitet.

Glooko wird die digitale JITAI Coaching Software von xbird in seine bestehende Plattform integrieren, die täglich von 7.500 Gesundheitseinrichtungen und mehr als 1,5 Millionen Patienten weltweit genutzt wird. Glooko plant, die neue Lösung allen Nutzer seiner Plattform weltweit zugänglich zu machen, damit sie mit ihrem Diabetes und damit zusammenhängenden chronischen Erkankungen besser leben können.

###

Über chronische Erkrankungen*
Weltweit leiden ungefähr 537 Millionen Erwachsene an Diabetes, darunter alleine 9,5 Millionen in Deutschland, d.h. 15,3% der Bevölkerung – Tendenz steigend. Deutschland befindet sich weltweit unter den Top 10 Ländern mit dem stärksten Anstieg an Diabetes. Darüber hinaus leidet fast die Hälfte aller über 15jährigen Deutschen an zwei oder mehreren chronischen Erkrankungen (verglichen mit einem Drittel der Weltbevölkerung). Nach Angaben des European Observatory on Health Systems and Policies ist einer von sechs Erwachsenen in Deutschland übergewichtig.

Über Glooko
Glooko verändert das digitale Gesundheitswesen, indem es Menschen mit Diabetes und verwandten Krankheiten und ihre medizinischen Betreuer miteinander vernetzt und so Telemedizin, klinische Forschung und bessere medizinische Ergebnisse ermöglicht. Die Software-Plattformen des Unternehmens unterstützen das Management von Diabetes und anderen chronischen Erkrankungen, indem sie die Daten von medizinischen Geräten und Apps nach höchsten Sicherheitsstandards verarbeiten. Die Daten werden per App oder in der Klinik hochgeladen und in aussagekräftigen Diagrammen und Grafiken visualisiert. Die Plattformen sind mit über 95% der weltweit erhältlichen Diabetes- und Gesundheitsüberwachungsgeräte kompatibel, so dass Menschen mit Diabetes und anderen chronischen Erkrankungen und ihre Pflegeteams die freie Wahl zwischen marktüblichen Geräten haben. Mehr als 3 Millionen Nutzer profitieren bereits von Glookos Lösungen zur Verarbeitung ihrer Gesundheitsdaten. Die Produkte werden von weltweit führenden Anbietern im Bereich Diabetes und chronische Erkrankungen genutzt und sind in 29 Ländern und 22 Sprachen verfügbar. Erfahren Sie mehr auf glooko.com.

Über xbird
xbird setzt Künstliche Intelligenz (KI) in der Medizin ein, um Lösungen zur Vorhersage von Gesundheitsrisiken und der Unterstützung von Diabetesmanagement zu entwickeln. Das Unternehmen sammelt Daten mithilfe von eingebauten Sensoren an Smartphones, Wearables, und medizinischen Geräten und entwickelt Algorithmen und Modelle von maschinellem Lernen, die auf Grundlage dieser Daten digitale Interventionssysteme (JITAI) ermöglichen. Seit seiner Gründung im Jahr 2015 durch Sebastian Sujka und Matteo Carli arbeitet xbird mit großen Pharma- und Medizintechnikunternehmen in Europa und den USA zusammen, um basierend auf KI individuelle Lösungen für Patientenverhalten und Therapieunterstützung anzubieten.

* Quellen:
1. International Diabetes Foundation
2. https://www.oecd-ilibrary.org//sites/5101558b-en/index.html?itemId=/content/component/5101558b-en#
3. OECD/European Observatory on Health Systems and Policies (2019), Germany: Country Health Profile 2019, State of Health in the EU, OECD Publishing, Paris/European Observatory on Health Systems and Policies, Brussels.

###

Medienanfragen
Tanya Rodante
Director of Communication, Glooko
[email protected]

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
[email protected]
T: +49 40 88 16 59 64 /
T: +49 30 23 63 27 68

Acquisition expands Glooko’s digital health capabilities with machine learning

BERLIN and PALO ALTO, California, January 31, 2022 /PRNewswire/ – Glooko, Inc., a leading provider of remote patient monitoring and digital health solutions for diabetes and other chronic conditions today announced it has acquired xbird, a Berlin-based health AI company developing JITAI (Just In Time Adaptive Intervention) technologies to support patients and their providers in predicting behavior and managing diabetes.

Using the latest AI and machine learning, xbird’s technology has the capability of identifying health risks for people with diabetes by interpreting medical and behavioral data in a targeted manner and providing customized recommendations and behavioral nudges. Sensors via smartphones and wearables record a user’s movements and analyze the data to create individualized behavioral profiles and personalized nudges to change patient behavior and lifestyle decisions. The addition of xbird expands Glooko’s advanced analytics capabilities and tools, further broadening Glooko’s platform offerings.

“We are thrilled to welcome the xbird team to the Glooko family. Our investment in xbird represents Glooko’s strategic commitment to machine learning and customized digital coaching for patients with chronic conditions,” said Russ Johannesson, Glooko’s Chief Executive Officer. “Among the many JITAI companies in the digital health landscape, xbird clearly has a superior solution, and has built successful partnerships throughout diabetes device manufacturers and clinical institutions. The combination of Glooko’s established global footprint and xbird’s exciting JITAI capabilities will allow us to improve patient outcomes.”

Sebastian Sujka, Chief Executive Officer and Co-Founder of xbird stated, “xbird and Glooko are a great fit. We share a commitment to providing solutions that address multiple chronic conditions, delivering measurable outcomes, and we have a common mission to broadly serve all patients in need. Our goal is to continue the design of digital health solutions for those living with these conditions and to make our capabilities accessible to as many patients as possible.” Mr. Sujka will join Glooko as the Managing Director of Glooko GmbH, along with all of the xbird staff.

Glooko will integrate the xbird JITAI digital coaching software with its established platform which is used daily by more than 7500 clinics globally and over 1M users. Glooko plans to enable users of their platform globally to utilize these solutions to better manage their diabetes and related chronic conditions.

The Prevalence of Chronic Disease*
Approximately 537 million adults are living with diabetes worldwide, with 9.5 million in Germany (15.3% of the population) and the numbers continue to rise. It is ranked in the top 10 global countries with the fastest growth in diabetes. Additionally, almost one in two people in Germany over 15 years report living with two or more chronic conditions (versus approximately one third of people worldwide). According to the European Observatory on Health Systems and Policies, one in six adults are considered to be obese in Germany.

About Glooko
Glooko is transforming digital health by connecting people with diabetes and other chronic conditions with their healthcare teams, enabling collaborative telehealth, clinical research and improved health outcomes. The company’s software platforms collect and analyze data from multiple devices in one highly secure place, allowing for easy remote upload via app or in-clinic, and producing easy-to-read analytics through actionable charts and graphs. The platform is compatible with over 95% of global diabetes and health monitoring devices, giving patients and their providers flexibility in how to manage their conditions. More than 3 million users have already benefited from Glooko’s solutions in 29 countries across 22 languages. Learn more at glooko.com.

About xbird
xbird is a medical AI company developing ways to predict health risks and support diabetes management. The company captures data streams from built-in sensors on smartphones, wearables, and medical devices to develop algorithms and machine learning models which process these streams into real-time just in time adaptive interventions (JITAI). Founded in 2015 by Sebastian Sujka and Matteo Carli, xbird has collaborated with major European and US pharma and medical device companies to customize patient interaction and engagement with artificial intelligence.

* Sources:
1. International Diabetes Foundation
2. https://www.oecd-ilibrary.org//sites/5101558b-en/index.html?itemId=/content/component/5101558b-en#
3. OECD/European Observatory on Health Systems and Policies (2019), Germany: Country Health Profile 2019, State of Health in the EU, OECD Publishing, Paris/European Observatory on Health Systems and Policies, Brussels.

###

Media Inquiries
Tanya Rodante
Director of Communication, Glooko
[email protected]

Forschungsdaten belegen: Vernetzte Pens verbessern Einhaltung regelmäßiger Insulindosierungen deutlich; ermöglichen längere Aufrechterhaltung des empfohlenen Glukosebereichs

GOTHENBURG, Schweden, 9. November 2021 /PRNewswire/ — Glooko Inc., ein führender Anbieter von Fernüberwachungs- und Datenmanagementlösungen für Diabetes und andere chronische Erkrankungen, gab heute eine strategische Zusammenarbeit mit Novo Nordisk bei der Entwicklung von vernetzten Insulin-Pen-Lösungen bekannt, die Menschen mit Diabetes in Deutschland und anderen europäischen Märkten zugute kommen wird. Im Rahmen dieser Zusammenarbeit integrieren die Unternehmen zwei neue vernetzte, intelligente Insulinpens, den NovoPen® 6 und den NovoPen Echo® Plus, in die mobilen Apps und cloudbasierten Plattformen von Glooko.

Die Plattformen von Glooko sind mit mehr als 95 Prozent der weltweit angebotenen Diabetesgeräte kompatibel. Die Zusammenarbeit mit Novo Nordisk baut auf dem geräteübergreifenden Geschäftsmodell des Unternehmens zur Fernüberwachung von Patienten und zum Management von Daten auf. Damit werden die Möglichkeiten des Versorgungsmanagements für Menschen mit Diabetes und ihre Gesundheitsdienstleister erweitert und können individuell angepasst werden.

Die neuen intelligenten Stifte zeichnen automatisch Dosierungszeiten und -mengen auf, speichern diese Daten bis zu drei Monate und ermöglichen die Übertragung in die Glooko-Plattform. Anders als herkömmliche Insulinpens, bei denen der Benutzer alle Daten zu jeder Insulindosis manuell aufzeichnen muss, ermöglichen die neuen Smart Pens nicht nur die lückenlose digitale Aufzeichnung der Insulindosierungsdaten, sondern bieten auch die Möglichkeit, die aufgezeichneten Daten per Nahfeldkommunikation (NFC) zu übertragen.

Durch die Integration der Berichts- und Analysefunktionen der Glooko®-Plattform ermöglichen die neuen intelligenten Pens den Patienten die Erfassung sämtlicher Dosierungsdaten und helfen ihnen und ihren Betreuern, verpasste Insulindosen schnell zu erkennen. Die Glooko-Integration ermöglicht es den Patienten auch, grafisch aufbereitete Daten einzusehen, die ihnen helfen, Trends zu erkennen und ihren Behandlungsplan zu verbessern.

„Wir freuen uns sehr über die Zusammenarbeit mit Novo Nordisk zur Integration unserer Diabetes-Produkte”, sagte Russ Johannesson, CEO von Glooko. „Studien haben gezeigt, dass sich Behandlungsergebnisse verbessern lassen, wenn intelligente Insulingeräte mit digitalen Gesundheitslösungen synchronisiert werden. Wir freuen uns über den weiteren Ausbau unserer Zusammenarbeit mit Novo Nordisk und darauf, Menschen in Deutschland zukünftig weitere innovative Produkte für eine verbesserte Einhaltung von Behandlungsplänen anbieten zu können.”
Der NovoPen 6 wurde in einer kürzlich in 12 Diabeteskliniken in ganz Schweden durchgeführten ersten Ergebnisstudie zum Einsatz von Smart Pens in der klinischen Praxis an Patienten getestet. Die Studie zeigte, dass sich die Anzahl der vergessenen Insulindosen zu den Mahlzeiten um 43 Prozent reduzierte (P=0,002). Außerdem erhöhte sich die Dauer, in der die Glukosewerte im empfohlenen Bereich lagen, deutlich, und zwar von 41,4 auf 49,9 Prozent (P<0,001).^[1]

Glooko ist der weltweit führende Anbieter von Diabetes-Patientendaten, die über 32 Milliarden Datenpunkte umfassen. Durch die Integration der vernetzten Insulinpens von Novo Nordisk erhält Glooko Zugang zu weiteren Daten für zusätzliche internationale Märkte. Dies wird Gesundheitsdienstleistern und klinischen Forschern auf der ganzen Welt nutzen, indem sie Zugang zu weiteren klinischen Daten erhalten und diese in Studien zur Verbesserung von Therapien für Patienten mit chronischen Erkrankungen verwenden können.

Informationen zu Glooko
Glooko verändert das digitale Gesundheitswesen, indem es Menschen mit Diabetes und verwandten Krankheiten mit ihren medizinischen Betreuern vernetzt und so Telemedizin, klinische Forschung und eine verbesserte Zusammenarbeit ermöglicht. Die Software-Plattformen des Unternehmens, Glooko® und diasend®, unterstützen das Management von Diabetes und anderen chronischen Erkrankungen, indem sie die Daten von Blutzuckermessgeräten, CGMs, Insulinpumpen, vernetzten Insulin-Pens, Blutdruckmanschetten, Ernährungs-Apps, vernetzten Waagen und Aktivitäts-Trackern sammeln und nutzbar machen – und die Erkenntnisse an einem Ort zusammenführen. Die Daten werden per App oder in der Klinik einfach hochgeladen, unter hohen Sicherheitsstandards übermittelt und in aussagekräftigen Diagrammen und Grafiken visualisiert. Dies ermöglicht eine effiziente Zusammenarbeit von Patienten, Pflegern und Medizinern sowie sichere Behandlungsentscheidungen. Die Plattformen sind mit über 95 % der weltweit erhältlichen Diabetes- und Gesundheitsüberwachungsgeräte kompatibel, so dass Menschen mit Diabetes und anderen chronischen Erkrankungen und ihre Pflegeteams die freie Wahl zwischen marktüblichen Geräten haben. Mehr als 3 Millionen Nutzer profitieren bereits von den Lösungen von Glooko zur Verarbeitung ihrer Gesundheitsdaten. Die Produkte werden von weltweit führenden Anbietern im Bereich Diabetes und chronische Erkrankungen genutzt und sind in 29 Ländern und 22 Sprachen verfügbar. Erfahren Sie mehr auf glooko.com.

Medienanfragen Nordamerika
Tanya Rodante
Direktorin für Kommunikation, Glooko
[email protected]

Medienanfragen Europa
Anders Sonesson
General Manager EMEA/APAC, Glooko
[email protected]
+46735458888

Medienanfragen Deutschland
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
[email protected]
T: +49 40 88 16 59 64 /
T: +49 30 23 63 27 68

[1] Adolfsson P, Hartvig NV, Kaas A, Moller JB, Hellman J: Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen. Diabetes Technology & Therapeutics 2020;22:709-718.